Notice Regarding the Acquisition of the Edaravone Business for the Treatment of Amyotrophic Lateral Sclerosis by Tanabe Pharma

Overview of the Transaction

Shionogi & Co., Ltd. resolved at its Board of Directors meeting on December 22, 2025, to conclude an agreement to acquire all global rights, including intellectual property and sales rights, for Edaravone, a treatment for amyotrophic lateral sclerosis (ALS) and other conditions developed and marketed by Tanabe Pharma Corporation (product name in Japan: Radicut, product name in the US: Radicava). The transaction amount is 2.5 billion USD (approximately 394,175 million JPY). In the US, Shionogi Inc. will make the newly established Radicava business company a wholly owned subsidiary. The complete subsidiary acquisition of the Radicava business company is expected to occur after April 1, 2026, and the business is anticipated to contribute to revenue and profits from the fiscal year ending March 2027.

Purpose and Background of the Transaction

This acquisition is part of Shionogi’s strategy to realize one of its material issues, "Contributing to a Healthy and Enriched Life," by focusing on quality-of-life (QOL) diseases with high social impact, such as sleep disorders, hearing loss, and rare diseases. By acquiring full rights to Edaravone, an innovative treatment for the rare disease ALS that meets significant unmet medical needs, and incorporating personnel and business operation expertise experienced in rare disease domains, Shionogi aims to establish a strong sales foundation in the US market and accelerate the development and provision of rare disease therapies.